Search Results

Dr. Mehdi Shishehbor Appointed CMO of Inquis Medical

July 12, 2023—Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations based in Redwood City, California, announced the appointment of interventional cardiologist Mehdi H. Shishehbor, DO, as Chief Medical Officer.

DCB Compared to BMS in Femoropopliteal Lesions in 3-Year Data From Four Studies

November 3, 2022—Mehdi Shishehbor, DO, presented 3-year results from a patient-level, propensity-adjusted comparison of drug-coated balloons (DCBs) versus bare metal stents (BMSs) in femoropopliteal lesions in prospective, multicenter studies.

Three-Month Data Analyzed for Experimental Drug JVS-100 to Enhance Wound Healing in CLI

March 12, 2018—Results of the STOP-PAD trial were presented by Mehdi Shishehbor, DO, in a Late Breaking Trial session at the American College of Cardiology's (ACC) 67th annual scientific session held March 10–12 in Orlando, Florida.

FDA Approves Pivotal Trial for QT Vascular's Chocolate Touch Drug-Coated Balloon

September 21, 2016—QT Vascular Ltd. has announced that the US Food and Drug Administration (FDA) granted the company conditional investigational device exemption approval to begin enrolling patients in the pivotal study of its Chocolate Touch drug-coated balloon (DCB).

Study Shows Prognostic Benefits of Postexercise ABI for Lower Extremity Revascularization

August 17, 2015—In a study published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions, Tarek A. Hammad, MD, et al concluded that postexercise ankle-brachial index (ABI) appears to offer both clinical (lower extremity revascularization) and prognostic information in patients with normal and abnormal resting ABIs (2015;8:1238–1244). The investigators, who are with the Cleveland Clinic in Cleveland, Ohio, were led by Mehdi Shishehbor, MD. 

Enrollment Begins in United States Pivotal Study of QT Vascular's Chocolate Touch DCB

August 3, 2017—QT Vascular Ltd. announced that it has commenced enrollment in its United States pivotal clinical study of the company's Chocolate Touch drug-coated balloon (DCB) for use in superficial femoral and popliteal arteries.

Multispecialty Coalition Develops Talking Points on Patient Safety for Treatment With Paclitaxel Device

October 6, 2020—The Multi-Specialty and Multi-Society Coalition for Patient Safety with Paclitaxel Technologies has developed a set of talking points for informing patients about the risks and benefits of paclitaxel-coated endovascular devices in the treatment of peripheral artery disease (PAD).

Study Assesses Safety and Efficacy of Radial Access for Peripheral Artery Interventions

October 16, 2023—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the publication of findings from a study evaluating the safety and feasibility of using radial access (RA) for complex endovascular lower extremity interventions to treat peripheral artery disease.

Full Approval Granted for Pivotal Trial of QT Vascular's Chocolate Touch Drug-Coated Balloon

December 16, 2016—QT Vascular Ltd. announced that the US Food and Drug Administration (FDA) has granted full approval of the investigational device exemption to enroll patients in the United States pivotal study of the Chocolate Touch drug-coated balloon (DCB) to treat peripheral artery disease in the superficial femoral and popliteal arteries.

LimFlow System’s PROMISE II Pivotal Trial Results Published

March 30, 2023—LimFlow SA, a developer of minimally invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), announced the publication of results from the PROMISE II United States pivotal trial that demonstrated the LimFlow system achieved a 66% rate of amputation-free survival at 6 months.